The LixiLan-L open-label trial compared the efficacy and safety of LixiLan, a novel fixed-ratio combination of insulin glargine (Gla-100) and lixisenatide, with Gla-100 over 30 weeks in patients with type 2 diabetes (T2D) inadequately controlled on basal insulin (± =2 oral antidiabetic drugs). In this analysis, safety and efficacy outcomes were assessed within subgroups according to baseline characteristics ([BC]; glycated hemoglobin [HbA1c] <8, =8%; body mass index <30, =30 kg/m2; duration of T2D <10, =10 years). Reduction in HbA1c, proportion of responders achieving HbA1c <7%, and incidence of hypoglycemia (=70 mg/dL) for the BC subgroups are shown (Table). There were no major changes in parameters across subgroups and efficacy was maintained in patients with high HbA1c. The LixiLan treatment group showed consistently greater glycemic control and more responders compared with the Gla-100 group in all of the subpopulations tested. Hypoglycemia varied slightly for subgroups (Table), without marked differences observed. In conclusion, LixiLan consistently improved glycemic control compared with Gla-100 in all subgroups of BC, including the most challenging groups of patients with long duration of diabetes, obesity, and high HbA1c.